Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00268
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
PDC-5b
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer
|
|||||
| Structure |
|
|||||
| Peptide Name |
[K4,F7,K22,P34]-NPY
|
Peptide Info | ||||
| Receptor Name |
Neuropeptide Y receptor type 1 (NPY1R)
|
Receptor Info | ||||
| Drug Name |
Methotrexate
|
Drug Info | ||||
| Therapeutic Target |
Reduced folate transporter (SLC19A1)
|
Target Info | ||||
| Linker Name |
GFLG
|
Linker Info | ||||
| Formula |
C237H341N65O63
|
|||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight | 5108.727 | ||||
| Lipid-water partition coefficient (xlogp) | -13.66053 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 65 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 69 | |||||
| Rotatable Bond Count (rotbonds) | 160 | |||||
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
3.0 (8.5 ± 0.1) nM
|
|||
| In Vitro Model | Normal | COS-7 cell | CVCL_0224 | ||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
226 (6.6 ± 0.1) nM
|
|||
| In Vitro Model | Normal | COS-7 cell | CVCL_0224 | ||
| Experiment 3 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
3.6 (5.4 ± 0.1) μM
|
|||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cell | CVCL_0419 | ||
| Experiment 4 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
7.7 (5.1 ± 0.1) μM
|
|||
| In Vitro Model | Invasive breast carcinoma | T-47D cell | CVCL_0553 | ||
| Experiment 5 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
8.1 (5.1 ± 0.1) μM
|
|||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cell | CVCL_0062 | ||
References